{"id":743,"date":"2019-04-07T20:28:06","date_gmt":"2019-04-07T11:28:06","guid":{"rendered":"https:\/\/www.urogynnet.jp\/?p=743"},"modified":"2020-09-12T21:24:17","modified_gmt":"2020-09-12T12:24:17","slug":"%e3%82%a4%e3%83%9f%e3%83%80%e3%83%95%e3%82%a7%e3%83%8a%e3%82%b7%e3%83%b3%e3%81%af%e9%81%8e%e6%b4%bb%e5%8b%95%e8%86%80%e8%83%b1%e7%97%87%e5%80%99%e7%be%a4%e6%82%a3%e8%80%85%e3%81%ae%e3%81%9f%e3%82%81","status":"publish","type":"post","link":"https:\/\/www.urogynnet.jp\/%e3%82%a4%e3%83%9f%e3%83%80%e3%83%95%e3%82%a7%e3%83%8a%e3%82%b7%e3%83%b3%e3%81%af%e9%81%8e%e6%b4%bb%e5%8b%95%e8%86%80%e8%83%b1%e7%97%87%e5%80%99%e7%be%a4%e6%82%a3%e8%80%85%e3%81%ae%e3%81%9f%e3%82%81\/","title":{"rendered":"\u30a4\u30df\u30c0\u30d5\u30a7\u30ca\u30b7\u30f3\u306f\u904e\u6d3b\u52d5\u8180\u80f1\u75c7\u5019\u7fa4\u60a3\u8005\u306e\u305f\u3081\u306e\u73fe\u5728\u306e\u6297\u30e0\u30b9\u30ab\u30ea\u30f3\u85ac\u306e\u4ee3\u66ff\u54c1\u304b\uff1f"},"content":{"rendered":"\n


Is imidafenacin an alternative to current antimuscarinic drugs for patients with overactive bladder syndrome?
Jia-Pei Wu, Liao Peng, Xiao Zeng, Hao Li, Hong Shen & De-Yi Luo
International Urogynecology Journal (2020)<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

\u6982\u8981
\u76ee\u7684
\u4ee5\u524d\u306e\u7814\u7a76\u306b\u306f\u9650\u3089\u308c\u305f\u6570\u306e\u30e9\u30f3\u30c0\u30e0\u5316\u6bd4\u8f03\u8a66\u9a13\uff08RCT\uff09\u304c\u542b\u307e\u308c\u3066\u304a\u308a\u3001\u904e\u6d3b\u52d5\u8180\u80f1\u75c7\u5019\u7fa4\uff08OAB\uff09\u306b\u5bfe\u3059\u308b\u30a4\u30df\u30c0\u30d5\u30a7\u30ca\u30b7\u30f3\u3068\u4ed6\u306e\u6297\u30b3\u30ea\u30f3\u85ac\uff08AD\uff09\u306b\u3088\u308b\u6cbb\u7642\u5f8c\u306e\u9650\u3089\u308c\u305f\u30d1\u30e9\u30e1\u30fc\u30bf\u30fc\u3092\u6bd4\u8f03\u3057\u3066\u304a\u308a\u3001\u3053\u308c\u3089\u306eAD\u306e\u512a\u4f4d\u6027\u306b\u3064\u3044\u3066\u306e\u8ad6\u4e89\u306f\u307e\u3060\u6b8b\u3063\u3066\u3044\u307e\u3059\u3002\u79c1\u305f\u3061\u306f\u8a3c\u62e0\u3092\u66f4\u65b0\u3057\u3001\u3088\u308a\u826f\u3044\u81e8\u5e8a\u30ac\u30a4\u30c0\u30f3\u30b9\u3092\u63d0\u4f9b\u3059\u308b\u3053\u3068\u3092\u76ee\u6307\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n\n\n\n

\u65b9\u6cd5
2007\u5e741\u6708\u304b\u30892019\u5e744\u6708\u307e\u3067\u3001PubMed\u3001Embase\u3001ClinicalTrial.gov\u3001\u304a\u3088\u3073Cochrane Library Controlled of Controlal Trials \u306e\u4f53\u7cfb\u7684\u306a\u691c\u7d22\u304c\u884c\u308f\u308c\u307e\u3057\u305f\u3002OAB\u60a3\u8005\u306e\u30a4\u30df\u30c0\u30d5\u30a7\u30ca\u30b7\u30f3\u3068\u4ed6\u306eAD\u3092\u6bd4\u8f03\u3059\u308b\u3059\u3079\u3066\u306e\u516c\u958b\u3055\u308c\u305fRCT\u306e\u30e1\u30bf\u5206\u6790\u304c\u884c\u308f\u308c\u307e\u3057\u305f\u3002\u4e3b\u306a\u7d50\u679c\u306f\u3001OAB\u75c7\u72b6\u3068OAB\u75c7\u72b6\u30b9\u30b3\u30a2\uff08OABSS\uff09\u306e\u5909\u5316\u3067\u3057\u305f\u3002\u526f\u6b21\u7684\u7d50\u679c\u306b\u306f\u3001\u6709\u5bb3\u4e8b\u8c61\uff08AE\uff09\u3068AE\u306b\u95a2\u9023\u3059\u308b\u30c9\u30ed\u30c3\u30d7\u30a2\u30a6\u30c8\u7387\u304c\u542b\u307e\u308c\u307e\u3059\u3002<\/p>\n\n\n\n

\u7d50\u679c
23.43\u9031\u9593\u306e\u5e73\u5747\u8ffd\u8de1\u8abf\u67fb\u304c\u884c\u308f\u308c\u305f1430\u4eba\u306e\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f7\u3064\u306eRCT\u3092\u542b\u3080\u5408\u8a086\u3064\u306e\u7814\u7a76\u304c\u542b\u307e\u308c\u307e\u3057\u305f\u3002\u3059\u3079\u3066\u306e\u5e83\u544a\u306fOAB\u306e\u75c7\u72b6\u3092\u6539\u5584\u3057\u307e\u3057\u305f\u3002\u6709\u52b9\u6027\u306b\u95a2\u3057\u3066\u3001\u3053\u308c\u3089\u306e\u85ac\u7269\u306f\u3001\u6392\u5c3f\u3001\u7dca\u6025\u30a8\u30d4\u30bd\u30fc\u30c9\u3001\u7dca\u6025\u6027\u5c3f\u5931\u7981\u30a8\u30d4\u30bd\u30fc\u30c9\u3001\u5c3f\u5931\u7981\u30a8\u30d4\u30bd\u30fc\u30c9\u304a\u3088\u3073OABSS\u3067\u540c\u69d8\u306e\u6709\u52b9\u6027\u3092\u793a\u3057\u307e\u3057\u305f\u3002\u3057\u304b\u3057\u3001\u30a4\u30df\u30c0\u30d5\u30a7\u30ca\u30b7\u30f3\u306f\u591c\u9593\u983b\u5c3f\u30a8\u30d4\u30bd\u30fc\u30c9\u306e\u6e1b\u5c11\u306b\u512a\u308c\u3066\u3044\u307e\u3057\u305f\uff08MD = \u20130.24\u300195\uff05CI \u20130.44\u301c\u20130.04\u3001P \u2009= 0.02\uff09\u3002\u3055\u3089\u306b\u3001\u30a4\u30df\u30c0\u30d5\u30a7\u30ca\u30b7\u30f3\u306f\u7d71\u8a08\u7684\u306b\u4f4e\u3044\u53e3\u6e07\u7387\uff08RR = 0.87\u300195\uff05CI 0.75\u301c1.00\u3001P \u2009= 0.04\uff09\u3001\u4fbf\u79d8\u7387\uff08RR = 0.68\u300195\uff05CI 0.50\u301c0.93\u3001P \u2009= 0.01\uff09\u304a\u3088\u3073\u305d\u308c\u4ee5\u4e0b\u3068\u95a2\u9023\u3057\u3066\u3044\u305fAE\u95a2\u9023\u96e2\u8131\u7387\uff08RR = 0.51\u300195\uff05CI 0.29\u20130.89\u3001P \u2009= 0.02\uff09\u3002\u4ed6\u306e\u5408\u4f75\u75c7\u306b\u95a2\u3057\u3066\u306f\u6709\u610f\u5dee\u306f\u3042\u308a\u307e\u305b\u3093\u3067\u3057\u305f\u3002<\/p>\n\n\n\n

\u7d50\u8ad6
\u7d50\u8ad6\u3068\u3057\u3066\u3001\u30a4\u30df\u30c0\u30d5\u30a7\u30ca\u30b7\u30f3\u306fOAB\u306e\u6cbb\u7642\u306b\u304a\u3044\u3066\u4ed6\u306eAD\u3068\u540c\u7b49\u3067\u3057\u305f\u3002\u3055\u3089\u306b\u3001\u30a4\u30df\u30c0\u30d5\u30a7\u30ca\u30b7\u30f3\u306f\u3088\u308a\u4f4e\u3044\u53e3\u6e07\u7387\u3001\u3088\u308a\u4f4e\u3044\u4fbf\u79d8\u7387\u3001\u3088\u308a\u9ad8\u3044\u30a2\u30c9\u30d2\u30a2\u30e9\u30f3\u30b9\u3068\u6301\u7d9a\u6027\u3092\u793a\u3057\u307e\u3057\u305f\u3002<\/p>\n\n\n\n

(\u89e3\u8aac\uff09
\u30a4\u30df\u30c0\u30d5\u30a7\u30ca\u30b7\u30f3\u306f\u3001\u30e0\u30b9\u30ab\u30ea\u30f3\u6027\u30a2\u30bb\u30c1\u30eb\u30b3\u30ea\u30f3\u53d7\u5bb9\u4f53\u963b\u5bb3\u85ac\u3067\u3001\u6297\u30b3\u30ea\u30f3\u85ac\u306e\u4e00\u3064\u3002\u30a2\u30bb\u30c1\u30eb\u30b3\u30ea\u30f3\u306b\u3088\u308b\u30e0\u30b9\u30ab\u30ea\u30f3\u53d7\u5bb9\u4f53\u30b5\u30d6\u30bf\u30a4\u30d7\u3078\u306e\u523a\u6fc0\u3092\u963b\u5bb3\u3059\u308b\u3053\u3068\u3067\u85ac\u52b9\u3092\u767a\u73fe\u3059\u308b\u3002\u4e3b\u306b\u904e\u6d3b\u52d5\u8180\u80f1\u306b\u3088\u308b\u983b\u5c3f\u306a\u3069\u306b\u7528\u3044\u3089\u308c\u308b\u3002
\u5546\u54c1\u540d\u306f\u3001\u30a6\u30ea\u30c8\u30b9\u3068\u3044\u3046\u3002\u4ed6\u306e\u6297\u30b3\u30ea\u30f3\u85ac\u3068\u9055\u3046\u306e\u306f\u30011\u65e52\u56de\u306b\u308f\u3051\u3066\u5185\u670d\u3059\u308b\u3053\u3068\u3067\u3042\u308b\u3002\u3053\u306e\u305f\u3081\u3001\u6295\u4e0e\u91cf\u306e\u8abf\u7bc0\u304c\u53ef\u80fd\u306b\u306a\u308b\u3002
1993\u5e74\u306b\u674f\u6797\u88fd\u85ac\u682a\u5f0f\u4f1a\u793e\u3068\u5c0f\u91ce\u85ac\u54c1\u5de5\u696d\u682a\u5f0f\u4f1a\u793e\u304c\u5171\u540c\u958b\u767a\u3092\u59cb\u3081\u305f\u30021997\u5e74\u3088\u308a\u81e8\u5e8a\u8a66\u9a13\u3092\u958b\u59cb\u3057\u3001\u904e\u6d3b\u52d5\u8180\u80f1\u75c7\u72b6\u306b\u5bfe\u3057\u3066\u512a\u308c\u305f\u6709\u52b9\u6027\u304a\u3088\u3073\u5b89\u5168\u6027\u304c\u78ba\u8a8d\u3055\u308c\u305f\u30022007\u5e744\u6708\u306b\u300c\u904e\u6d3b\u52d5\u8180\u80f1\u306b\u304a\u3051\u308b\u5c3f\u610f\u5207\u8feb\u611f\u3001\u983b\u5c3f\u304a\u3088\u3073\u5207\u8feb\u6027\u5c3f\u5931\u7981\u300d\u306e\u52b9\u80fd\u30fb\u52b9\u679c\u3001\u300c\u901a\u5e38\u3001\u6210\u4eba\u306b\u306f\u30a4\u30df\u30c0\u30d5\u30a7\u30ca\u30b7\u30f3\u3068\u3057\u30661\u56de0.1mg\u30921\u65e52\u56de\u3001\u671d\u98df\u5f8c\u304a\u3088\u3073\u5915\u98df\u5f8c\u306b\u7d4c\u53e3\u6295\u4e0e\u3059\u308b\u300d\u306e\u7528\u6cd5\u30fb\u7528\u91cf\u3067\u88fd\u9020\u627f\u8a8d\u3092\u5f97\u305f\u3002
\u3057\u305f\u304c\u3063\u3066\u3001\u7814\u7a76\u306f\u300110\u5e74\u4ee5\u4e0a\u7d4c\u904e\u3057\u3066\u306e\u3061\u306e\u4fe1\u983c\u3092\u304a\u3051\u308b\u3082\u306e\u306b\u306a\u3063\u3066\u3044\u308b\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"Is imidafenacin an alternative to current antimuscarinic drugs for patients with overactive bladder syndrome?J […]","protected":false},"author":1,"featured_media":744,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21],"tags":[26,25],"_links":{"self":[{"href":"https:\/\/www.urogynnet.jp\/wp-json\/wp\/v2\/posts\/743"}],"collection":[{"href":"https:\/\/www.urogynnet.jp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.urogynnet.jp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.urogynnet.jp\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.urogynnet.jp\/wp-json\/wp\/v2\/comments?post=743"}],"version-history":[{"count":1,"href":"https:\/\/www.urogynnet.jp\/wp-json\/wp\/v2\/posts\/743\/revisions"}],"predecessor-version":[{"id":745,"href":"https:\/\/www.urogynnet.jp\/wp-json\/wp\/v2\/posts\/743\/revisions\/745"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.urogynnet.jp\/wp-json\/wp\/v2\/media\/744"}],"wp:attachment":[{"href":"https:\/\/www.urogynnet.jp\/wp-json\/wp\/v2\/media?parent=743"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.urogynnet.jp\/wp-json\/wp\/v2\/categories?post=743"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.urogynnet.jp\/wp-json\/wp\/v2\/tags?post=743"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}